Literature DB >> 2715642

Class II restriction in mice to the malaria candidate vaccine ring infected erythrocyte surface antigen (RESA) as synthetic peptides or as expressed in recombinant vaccinia.

A M Lew1, C J Langford, D Pye, S Edwards, L Corcoran, R F Anders.   

Abstract

The immune response to three peptides corresponding to the repeat regions of the malaria candidate vaccine ring infected E surface Ag (RESA) were studied. Both antibody responses and lymphocyte stimulation in mice injected with these peptides without carrier were found to be restricted to certain MHC class II haplotypes. Mice bearing IAk were strong responders to all three peptides. Mice bearing IAd were strong responders only to the 3' repeat peptides, the octamer and tetramer. Mice bearing Is or Iq did not respond to any repeat peptides. Remarkably, the pattern of genetic restriction of the antibody response to the entire RESA as expressed in vaccinia indicated that there were no other epitopes besides the three repeats. Because only one class II haplotype (i.e., k) out of five tested responded strongly to this peptide and only two out of five (i.e., k and d) responded to the octamer or tetramer, it may be difficult to achieve a good immune response against RESA in most or all humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715642

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

2.  Genetic restriction and specificity of the immune response in mice to fusion proteins containing repeated sequences of the Plasmodium falciparum antigen Pf155/RESA.

Authors:  A Sjölander; R Andersson; M Hansson; K Berzins; P Perlmann
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

3.  H-2b restriction of the immune response to the p126 Plasmodium falciparum antigen.

Authors:  D M Banic; P Delplace; C Mazingue; D Camus
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

4.  Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria.

Authors:  D Pye; S J Edwards; R F Anders; C M O'Brien; P Franchina; L N Corcoran; C Monger; M G Peterson; K L Vandenberg; J A Smythe
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

5.  Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus.

Authors:  M Theisen; G Cox; B Høgh; S Jepsen; J Vuust
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Genetic regulation of human anti-malarial antibodies in twins.

Authors:  K Sjöberg; J P Lepers; L Raharimalala; A Larsson; O Olerup; N T Marbiah; M Troye-Blomberg; P Perlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

7.  Evidence for epitope-specific thymus-independent response against a repeat sequence in a protein antigen.

Authors:  N Kumar; H Zheng
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

8.  Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus.

Authors:  J A Tine; V Conseil; P Delplace; C De Taisne; D Camus; E Paoletti
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

9.  A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission.

Authors:  P N Fonjungo; I M Elhassan; D R Cavanagh; T G Theander; L Hviid; C Roper; D E Arnot; J S McBride
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

10.  Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens.

Authors:  D J Rawlings; D C Kaslow
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.